ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

NCT05366062 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioma, Malignant

Interventions

DRUG: ERC1671
DRUG: GM-CSF
DRUG: Cyclophosphamide
DRUG: Pembrolizumab

Sponsor

Epitopoietic Research Corporation